196 results
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
3:28pm
in numerous animal studies and dosing in clinical trials, our DNAbilize® drug candidates have demonstrated an excellent safety profile. DNAbilize® … that we may not be able to demonstrate the safety and efficacy of our drug candidates;
risks that our clinical trials may be delayed or terminated
8-K
EX-10.1
BPTH
Bio-Path Holdings Inc
19 Apr 24
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the- Market Under Nasdaq Rules
9:21am
and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result
424B5
BPTH
Bio-Path Holdings Inc
19 Apr 24
Prospectus supplement for primary offering
9:17am
tumors. Through testing in numerous animal studies and dosing in clinical trials, our DNAbilize® drug candidates have demonstrated an excellent safety … trials and the risk that we may not be able to demonstrate the safety and efficacy of our drug candidates;
risks that our clinical trials may be delayed
8-K
EX-99.1
BPTH
Bio-Path Holdings Inc
18 Apr 24
Other Events
9:13am
-Path studies have shown BP1002 to be a potent inhibitor against the Bcl-2 target, and we believe that its benign safety profile should enable effective … of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
Gail J
8-K
EX-10.1
sfoyo7f
4 Apr 24
Entry into a Material Definitive Agreement
4:35pm
424B5
f10esd80o
4 Apr 24
Prospectus supplement for primary offering
4:33pm
8-K
EX-99.1
d09yp
2 Apr 24
Bio-Path Holdings Provides 2024 Clinical and Operational Update
4:10pm
424B5
12nv2thc
27 Mar 24
Prospectus supplement for primary offering
8:15am
8-K
EX-10.1
kskc815cafi
26 Mar 24
Entry into a Material Definitive Agreement
8:03am
8-K
EX-99.1
ktpc 4unqjr
10 Jan 24
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline Therapy
4:10pm
8-K
EX-99.1
h6nn9nb818 rz0cx1v
14 Dec 23
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
4:05pm
8-K
EX-99.1
6vw h7t4ih7jmn
15 Aug 23
Bio-path Holdings Reports Second Quarter 2023 Financial Results
7:10am